Get the Stockscreener App
17.91
0.22%
+0.045
Morphosys AG ADR stock is currently priced at $17.91, with a 24-hour trading volume of 36,467.
It has seen a +0.22% increased in the last 24 hours and a -1.05% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $17.77 pivot point. If it approaches the $18.05 resistance level, significant changes may occur.
Previous Close:
$17.87
Open:
$17.86
24h Volume:
36,467
Market Cap:
$2.70B
Revenue:
$257.99M
Net Income/Loss:
$-206.62M
P/E Ratio:
28.79
EPS:
0.6223
Net Cash Flow:
$-474.15M
1W Performance:
-0.72%
1M Performance:
-1.05%
6M Performance:
+125.85%
1Y Performance:
+247.77%
1D Range:
$17.80
$17.91
52W Range:
$4.185
$18.30
Morphosys AG ADR Stock (MOR) Company Profile
Name
Morphosys AG ADR
Sector
Industry
Phone
49 89 89927 0
Address
Semmelweisstrasse 7, Planegg
Morphosys AG ADR Stock (MOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-13-23 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Sep-15-23 | Upgrade | Goldman | Sell → Neutral |
| Jul-17-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jun-16-23 | Upgrade | JP Morgan | Underweight → Overweight |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| May-31-23 | Initiated | UBS | Buy |
| Jan-06-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-15-22 | Downgrade | Citigroup | Neutral → Sell |
| Nov-15-22 | Downgrade | Stifel | Buy → Hold |
| Oct-24-22 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-13-21 | Resumed | Goldman | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Jun-03-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-24-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-18-20 | Initiated | Goldman | Neutral |
| Aug-10-20 | Initiated | Citigroup | Buy |
| Jun-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-12-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-05-18 | Initiated | Piper Jaffray | Overweight |
| Sep-07-18 | Downgrade | Berenberg | Buy → Hold |
| May-14-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Morphosys AG ADR Stock (MOR) Latest News
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Benzinga
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks Investment Research
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Zacks Investment Research
Novartis (NVS) to Undertake Job Cuts in Development Department
Zacks Investment Research
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
Zacks Investment Research
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
Zacks Investment Research
Morphosys AG ADR Stock (MOR) Financials Data
Morphosys AG ADR (MOR) Revenue 2024
MOR reported a revenue (TTM) of $257.99 million for the quarter ending December 31, 2023, a -10.96% decline year-over-year.
Morphosys AG ADR (MOR) Net Income 2024
MOR net income (TTM) was -$206.62 million for the quarter ending December 31, 2023, a -18.15% decrease year-over-year.
Morphosys AG ADR (MOR) Cash Flow 2024
MOR recorded a free cash flow (TTM) of -$474.15 million for the quarter ending June 30, 2023, a +21.05% increase year-over-year.
Morphosys AG ADR (MOR) Earnings per Share 2024
MOR earnings per share (TTM) was -$1.5029 for the quarter ending December 31, 2023, a -17.51% decline year-over-year.
About Morphosys AG ADR
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany.
0.83%
0.49%
Cap:
|
Volume (24h):